Rezolute Inc (RZLT)

Sector:
INFORMATION TECHNOLOGY
Industry:
SOFTWARE
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Nevan C. Elam
Employees:
30
1450 INFINITE DRIVE, LOUISVILLE, CO 80027
650-847-1919

Rezolute, Inc. develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulini® an ultra-rare pediatric genetic disorder.

Data derived from most recent annual or quarterly report
Market Cap 86.505 Million Shares Outstanding53.73 Million Avg 30-day Volume 37.783 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.92
Price to Revenue0.0 Debt to Equity0.0 EBITDA-44.409 Million
Price to Book Value0.9043 Operating Margin0.0 Enterprise Value-15.875 Million
Current Ratio64.07 EPS Growth0.474 Quick Ratio63.533
1 Yr BETA 0.4809 52-week High/Low 5.23 / 1.45 Profit Margin0.0
Operating Cash Flow Growth-75.9029 Altman Z-Score26.9369 Free Cash Flow to Firm -31.525 Million
Earnings Report2023-02-08

Are you looking for this stock instead?

View SEC Filings from RZLT instead.

View recent insider trading info

Funds Holding RZLT (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding RZLT

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-11-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-15:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-01:
    Item 1.02: Termination of a Material Definitive Agreement
    Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
  • 8-K: filed on 2022-06-17:
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-12:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-04:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-02:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-30:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-23:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-02-22:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    ELAM NEVAN C CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    2,600,000 2022-06-23 1

    LABRUCHERIE GIL M

    • Director
    80,000 2022-06-23 3

    KREHER NERISSA

    • Director
    80,000 2022-06-23 1

    HOGENHUIS WLADIMIR

    • Director
    80,000 2022-06-23 1

    KIM YOUNG-JIN

    • Director
    40,000 2022-06-23 1

    FAUCHET PHILIPPE

    • Director
    80,000 2022-06-23 1

    ROBERTS BRIAN KENNETH SR VP, CLINIC DEVELOPMENT

    • Officer
    700,000 2022-06-23 3

    HANDOK, INC.

    • 10% Owner
    102,665,019 2020-10-12 0

    LIM JUNGHEE

    • Director
    0 2019-11-20 0

    MANTRIPRAGADA SANKARAM CHIEF SCIENTIFIC OFFICER

    • Officer
    0 2019-07-31 0

    VENDOLA KEITH A. CHIEF FINANCIAL OFFICER

    • Officer
    0 2019-07-31 0

    GENEXINE INC.

    • 10% Owner
    148,119,108 2019-04-26 0

    MILLER SELINE E. VP FINANCE & CAO

    • Officer
    0 2019-03-04 0

    SUNG YOUNG CHUL

    • Director
    1,250,000 2019-02-11 0

    XOMA CORP

    • 10% Owner
    8,093,010 2018-04-23 0

    WELCH DAVID F

    • Director
    1,826,415 2017-03-08 0

    HUH HOYOUNG CHAIRMAN, SCIENTIFIC ADV. BD.

    • Officer
    • Director
    0 2016-10-31 0

    FIELDS MORGAN CHIEF ACCOUNTING OFFICER

    • Officer
    0 2016-10-31 0

    SHERMAN BARRY MICHAEL

    • Director
    0 2016-10-31 0

    HOWE STEVE

    • Director
    0 2014-04-30 0

    DOCKERY CARL

    ALPHA ADVISORS, LLC

    ALPHA VENTURE CAPITAL PARTNERS, L.P.

    • 10% Owner
    • SEE REMARKSSEE REMARKS
    1,152,847 2014-04-01 0

    KONUS ADVISORY GROUP, INC.

    • 10% Owner
    5,057,693 2014-03-26 0

    WOLKIN ORIT

    • 10% Owner
    0 2012-09-04 0

    KAEYO INVESTMENTS LTD

    • 10% Owner
    0 2012-09-04 0

    CHU JUE MIN

    • 10% Owner
    0 2012-09-04 0

    TURNOWSKI GUY SECRETARY

    • Officer
    • Director
    0 2012-09-04 0

    BAR NIR PRESIDENT AND TREASURER

    • Officer
    • Director
    • 10% Owner
    0 2012-09-04 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    REZOLUTE INC RZLT 2022-12-09 19:45:04 UTC 1.031 2.789 40000
    REZOLUTE INC RZLT 2022-12-09 19:15:04 UTC 1.031 2.789 40000
    REZOLUTE INC RZLT 2022-12-09 18:45:03 UTC 1.031 2.789 40000
    REZOLUTE INC RZLT 2022-12-09 18:15:03 UTC 1.031 2.789 40000
    REZOLUTE INC RZLT 2022-12-09 17:45:03 UTC 1.031 2.789 40000
    REZOLUTE INC RZLT 2022-12-09 17:15:03 UTC 1.031 2.789 40000
    REZOLUTE INC RZLT 2022-12-09 16:45:03 UTC 1.158 2.662 40000
    REZOLUTE INC RZLT 2022-12-09 16:15:03 UTC 1.158 2.662 40000
    REZOLUTE INC RZLT 2022-12-09 15:45:03 UTC 1.158 2.662 30000
    REZOLUTE INC RZLT 2022-12-09 15:15:03 UTC 1.158 2.662 30000
    REZOLUTE INC RZLT 2022-12-09 14:45:04 UTC 1.158 2.662 30000
    REZOLUTE INC RZLT 2022-12-09 14:15:03 UTC 1.158 2.662 30000
    REZOLUTE INC RZLT 2022-12-09 13:45:03 UTC 1.158 2.662 30000
    REZOLUTE INC RZLT 2022-12-09 13:15:03 UTC 1.158 2.662 30000
    REZOLUTE INC RZLT 2022-12-09 12:45:03 UTC 1.158 2.662 30000
    REZOLUTE INC RZLT 2022-12-08 22:15:03 UTC 1.158 2.662 40000
    REZOLUTE INC RZLT 2022-12-08 21:45:04 UTC 1.031 2.789 40000
    REZOLUTE INC RZLT 2022-12-08 21:15:03 UTC 1.031 2.789 40000
    REZOLUTE INC RZLT 2022-12-08 20:45:04 UTC 1.031 2.789 40000
    REZOLUTE INC RZLT 2022-12-08 20:15:05 UTC 1.031 2.789 40000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments